Stack of the Week: GLOW (GHK-Cu, BPC-157, TB-500)

GLOW is one of the most-discussed repair stacks. It combines three peptides: BPC-157, TB-500 and GHK-Cu. It is also sold premixed as a blend, the GLOW Blend, and it is the base that KLOW builds on by adding KPV.

The idea is that each peptide covers a different part of tissue repair. This piece looks at the evidence for each component on its own. One point up front, because it matters more than anything else here: no published study has tested GLOW as a unit. We found no trial, in animals or in humans, that gave all three peptides together. The closest study, covered below, paired only two of them in rats and found no added benefit.

The rationale in one paragraph

The pitch runs like this. BPC-157 supports soft-tissue repair and new blood vessel growth. TB-500 supports cell migration. GHK-Cu supports collagen production. Three mechanisms, three peptides. Each claim has some lab or animal support, as shown below. But "each part does something useful" is not evidence that the parts work better together, or even that they don't get in each other's way. That has to be tested directly, and it hasn't been.

GHK-Cu: the collagen piece

GHK is a tripeptide (three amino acids) found in human plasma. The "Cu" is copper. In the original 1980 work, the tripeptide was isolated alongside copper, readily formed copper complexes, and increased copper uptake into cultured liver-cancer cells. The authors suggested it may act as a copper-transport factor (Pickart 1980).

The collagen claim comes from two later studies:

• In cell culture, GHK-Cu increased collagen synthesis by fibroblasts (the cells that make connective tissue). The effect began at extremely low concentrations and did not depend on cell number (Maquart 1988).
• In rats, GHK-Cu injected into implanted wound chambers increased collagen, total protein and glycosaminoglycans (structural molecules in connective tissue) in a concentration-dependent way. A control tripeptide had no effect (Maquart 1993).

Evidence level: cell culture and animal models. The evidence behind injecting it as part of a repair stack is preclinical.

BPC-157: the soft-tissue piece

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Its best-known mechanism study used rat Achilles tendon cells. BPC-157 sped up the outgrowth of tendon fibroblasts from tendon tissue and helped the cells survive oxidative stress. It also increased cell migration in a dose-dependent way, likely through the FAK-paxillin signaling pathway. It did not directly increase how fast the cells divided (Chang 2011).

A 2025 systematic review is the most useful summary of where BPC-157 stands (Vasireddi 2025):

• Of 36 included studies, 35 were preclinical and one was clinical.
• In animal models, BPC-157 improved outcomes in muscle, tendon, ligament and bone injuries.
• Its reported half-life is under 30 minutes.
• "No clinical safety data were found."
• The authors flagged possible harms from "unregulated manufacturing, contamination, or unknown clinical safety."

The one human report is a retrospective chart review from a single clinic. Sixteen patients were reached by phone after knee injections. Eleven of the 12 who received BPC-157 alone reported significant improvement. No validated measures of function or pain were used, and there was no control group (Lee 2021). That is a starting point for a hypothesis, not evidence that the treatment works.

TB-500: the migration piece

TB-500 is usually described as a synthetic version of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide. It's worth being precise here. A doping-control study identified a seven-amino-acid acetylated fragment of Tβ4 (the 17-23 region) in a product sold as TB-500 (Esposito 2012). What is in a given "TB-500" vial may not be the full Tβ4 molecule the research was done on.

The research on Tβ4 itself:

• In normal and aged rodents, Tβ4 promoted new blood vessel growth, wound repair and hair growth by increasing angiogenesis and cell migration (Philp 2004).
• In diabetic and aged mice, Tβ4 sped up healing of full-thickness skin wounds. A seven-amino-acid synthetic peptide containing its actin-binding region (LKKTETQ) matched the full molecule in aged mice (Philp 2003).
• In humans, a phase 2 double-blind trial of topical Tβ4 randomized 73 patients with venous leg ulcers. Safety was comparable to placebo. The efficacy findings "suggest" the 0.03% dose "may have the potential" to speed healing, with complete healing within three months in about 25% of patients (Guarnera 2010).

Evidence level: animal data plus small phase 2 human trials of the full Tβ4 molecule, applied topically. That is not the same as injecting a product sold as TB-500.

The one combination study, and what it found

A 2026 rat study randomized 32 animals after Achilles tendon repair to four groups: control, BPC-157, TB-500, or both (Biçer 2026). The results:

• TB-500 alone produced a statistically significant gain in tendon strength (maximum load to failure) and better tissue scores.
• BPC-157 alone improved scores numerically, but not significantly on the total scores.
• Combining the two "did not confer additional benefits compared to either agent alone."

The authors suggested the two peptides may act through shared pathways, and said that idea itself needs testing. The study included no GHK-Cu, so it tells us nothing about the full GLOW trio. But it is the only direct test of any part of the combination, and it found no additive effect. For a closer look at these two peptides, see BPC-157 vs TB-500 and GHK-Cu vs BPC-157.

What we can and can't say

A 2026 review of peptides used in sports medicine reached a similar conclusion for the whole category. Many unapproved peptides show good tissue-repair results in animals, but "rigorous human safety data are scarce, and there is potential for serious harm" (Mendias 2026).

So GLOW is a reasonable-sounding idea built from three preclinical stories. Whether the combination helps, does nothing extra, or interacts in unknown ways has not been studied. Anyone reading about it should treat the stack as a hypothesis. Product quality is a separate problem. A blend is only as trustworthy as its certificate of analysis.

Sources

• Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature, 1980. PMID 7453802
• Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett, 1988. PMID 3169264
• In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest, 1993. PMID 8227353
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985), 2011. PMID 21030672
• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025. PMID 40756949
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 2021. PMID 34324435
• Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal, 2012. PMID 22962027
• Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev, 2004. PMID 15037013
• Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen, 2003. PMID 12581423
• The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci, 2010. PMID 20536470
• Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 2026. PMID 42542926
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 2026. PMID 41966639

This article is for educational and research purposes only and is not medical advice.